Mipomersen

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions

Abstract

Genzyme Corporation and Isis Pharmaceuticals have a worldwide licensing and collaboration agreement for the development of subcutaneous mipomersen (ISIS 147764; ISIS 301012; ISIS301012; mipomersen-sodium). Mipomersen, an oligonucleotide antisense inhibitor directed against apolipoprotein B-100 (apoB-100) mRNA, is in phase III clinical evaluation for the treatment of familial hypercholesterolemia, a form of type IIa hyperlipoproteinemia, and hypercholesterolemia in patients with severely high cholesterol levels or at high risk for coronary heart disease in the US, European Union, Brazil, Canada, South Africa, and South East Asia. This review discusses the development history and scientific profile of this new compound.

Citations

Nov 15, 2011·European Journal of Internal Medicine·Giuseppe Lippi, Emmanuel J Favaloro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Seminars in Thrombosis and Hemostasis
Nitin Kher, James D Marsh
Clinica Chimica Acta; International Journal of Clinical Chemistry
Giuseppe Lippi, G Guidi
© 2021 Meta ULC. All rights reserved